Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
A bid by GSK Plc (NYSE:GSK) and other pharmaceutical companies to halt over 70,000 lawsuits in Delaware concerning the discontinued heartburn drug Zantac has gained support from prominent U.S. industry groups.
藥品製造商glaxosmithkline Plc（紐交所：gsk）及其他製藥公司提出阻止超過70,000起關於已停產的胃痛藥Zantac的訴訟在德拉華州進行的要約，受到了美國著名行業團體的支持。
These groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America, argue that allowing the lawsuits to proceed jeopardizes Delaware's business-friendly reputation, Reuters reported.
據路透社報道，包括美國商會和製藥研究與製造商協會在內的這些團體認爲，允許訴訟繼續進行會危及德拉華州的商業友好聲譽。
Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac.
相關新聞: 吉利德的 Trodelvy 在普通膀胱癌最常見類型的後期研究中未能達到主要目標。輝瑞同意解決關於已停產的胃痛藥Zantac與癌症風險有關的10000多起訴訟。
The report noted that in a friend-of-the-court brief filed to the Delaware Superior Court, these groups expressed concerns that a recent ruling by Judge Vivian Medinilla could turn Delaware into a "hotbed of products-liability and mass-tort litigation."
報告指出，在提交給德拉華州高級法院的一份支持文件中，這些團體表達了擔憂，稱法官維維安·梅迪尼拉的最近裁決可能會使德拉華州成爲“產品責任和集體侵權訴訟的溫牀”。
The report adds that the brief highlights the potential negative impact on Delaware's judicial consistency and business climate if a more relaxed evidence standard is adopted for mass tort cases.
報告補充說，這份支持文件強調，如果爲集體侵權訴訟採取更寬鬆的證據標準，可能會對德拉華州的司法一致性和企業環境產生負面影響。
Pfizer Inc. (NYSE:PFE), Sanofi (NASDAQ:SNY), and Boehringer Ingelheim, all previous sellers of Zantac, joined GSK in requesting Judge Medinilla to prevent plaintiffs from presenting expert testimony linking Zantac to cancer.
輝瑞公司（紐交所：pfe），賽諾菲（納斯達克：sny）和勃林格殷格翰公司，作爲Zantac的前任銷售商，加入了gsk，要求梅迪尼拉法官阻止原告提出將Zantac與癌症聯繫起來的專家證言。
The companies argue that this testimony is not based on reliable scientific methods, which is critical for the plaintiffs' cases to proceed to trial.
這些公司認爲，這些證言不基於可靠的科學方法，這對於原告的案件進入審判至關重要。
Industry groups supporting this petition emphasize the need for clarity, consistency, and predictability in Delaware's handling of expert testimony in such cases.
支持此請願的行業團體強調，需要在德拉華州處理此類案件的專家證言方面具有明確性、一致性和可預見性。
They argue that Judge Medinilla's ruling contradicts a Florida federal court's 2022 decision, which dismissed about 50,000 similar claims after deeming the evidence unreliable. Some plaintiffs are appealing that decision.
他們認爲，梅迪尼拉法官的裁決與弗羅裏達聯邦法院2022年的判決相矛盾，後者經判定證據不可靠而駁回了約50,000起類似的索賠。一些原告正在上訴該決定。
Price Action: GSK shares are down 0.15% at $40.89 at last check Thursday.
股價行動：截至週四最後一次查看，gsk股價下跌0.15％，爲40.89美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明本內容部分由人工智能工具生成，並經Benzinga編輯審核和發佈。
Photo by Aunt Spray via Shutterstock
圖片來自Shutterstock的Aunt Spray
譯文內容由第三人軟體翻譯。